Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Corinne Goldsmith Dickinson Center for MS, New York

Maimonides MS Care Center, Brooklyn

SUNY Stony Brook, Stony Brook

University of Rochester, Rochester

Allegheny General Hospital, Allegheny Neurological Associates, Pittsburgh

Thomas Jefferson University Physicians, Philadelphia

Maryland Center for MS, Baltimore

Raleigh Neurology Associates, Raleigh

CMC - Neuroscience & Spine Institute, Division of Neurology, Charlotte

Shepherd Center, Atlanta

Ohio State University MS Center, Columbus

Cleveland Clinic Foundation, Cleveland

Indiana University MS Center, Indianapolis

Wayne State University, Department of Neurology, Detroit

The Schapiro Center for MS, Golden Valley

Advanced Neurology Specialists, Great Falls

University of Chicago, Chicago

Washington University School of Medicine, Div. of Rehab/Neurology, St Louis

University of Texas-Houston, Houston

Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center, Phoenix

USC, Keck School of Medicine Health Care Consultation Center, Los Angeles

UC Davis, Sacramento

Oregon Health & Science University, MS Center of Oregon, UHS-42, Portland

MS Center at Evergreen, Kirkland

Gimbel MS Center at Holy Name Hospital, Teaneck

Neurological Research Center, Inc., Bennington

Fletcher Allen Health Care, Burlington

Foothills Medical Center, Calgary

University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver

River Valley Health c/o Stan Cassidy Centre for Rehabilitation, Fredericton

QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site, Halifax

Ottawa Hospital General Campus, Ottawa